Passa al contenuto
Merck
HomeCross-CouplingP-Phos, PhanePhos and BoPhoz™ Ligands

P-Phos, PhanePhos and BoPhoz™ Ligands

P-Phos

The P-Phos ligand family was developed by Professor Chan of Hong Kong Polytechnic University and licensed to JM CCT in 2002. P-Phos is an atropisomeric biaryl bisphosphine with the unique feature of incorporating two methoxy-substituted pyridine rings in the backbone.1 This family of ligands often presents higher activity and selectivity than the analogous BINAP ligands in a series of reactions such as ruthenium catalyzed hydrogenation of β-ketoesters2 (Scheme 1) and rhodium- and ruthenium-catalyzed hydrogenation of dehydroamino acids (Scheme 2).3 Ru catalyzed hydrogenation of non-functionalized ketones is also highly effective using P-Phos ligands.4 Moreover, JM has further developed the scope of P-Phos Ru diamine complexes in ketone hydrogenation by the application of less traditional 1,3- and 1,4‑diamines (Scheme 3).5 Iridium-P-Phos catalysts have been recently used for the asymmetric hydrogenation of C=N bonds in quinolines (Scheme 4).6

Phanephos
Scheme 1

Scheme 1.

Scheme 2

Scheme 2.

Scheme 3

Scheme 3.

Scheme 4

Scheme 4.

Phanephos was first reported in 1997, and since then it has found applications in the rhodium-catalyzed hydrogenation of dehydroamino acids7 (Scheme 5) and the ruthenium-catalyzed hydrogenation of β-ketoesters (Scheme 6).8 Both rhodium and ruthenium catalysts bearing the Phanephos ligand show an exceptionally high activity in most homogeneous hydrogenation reactions.

BoPhoz
Scheme 5

Scheme 5.

Scheme 6

Scheme 6.

The BoPhoz class of ligands, based on the ferrocene backbone, have proven to be exceptionally active in many rhodium-catalyzed hydrogenations9 as well as being used in a number of rutheniumcatalyzed reactions. More recently Johnson-Matthey has developed new variants of BoPhoz ligands that offer increased structural and electronic diversity that may be required for the desired transformation. MeBoPhoz has shown excellent activity in many rhodium-catalyzed asymmetric hydrogenation of C=C bonds in dehydroaminoacids and α,β-unsaturated acids and esters (s/c up to 100,000) (Scheme 7).10

Scheme 7

Scheme 7.

The P-Cy-Me-BoPhoz ligand has been shown to catalyze the asymmetric reduction of α-ketoesters, which is unusual for a rhodium catalyst (Scheme 8).

Scheme 8

Scheme 8.

References

1.
Wu J, Chan ASC. 2006. P-Phos:  A Family of Versatile and Effective Atropisomeric Dipyridylphosphine Ligands in Asymmetric Catalysis. Acc. Chem. Res.. 39(10):711-720. https://doi.org/10.1021/ar0680015
2.
Wu C, Sun C. 2002. Soluble polymer-supported synthesis of 2-(arylamino)benzimidazoles. Tetrahedron Letters. 43(8):1529-1533. https://doi.org/10.1016/s0040-4039(02)00013-8
3.
Wu Jea. 2003. Tetrahedron: Asymmetry . 14987.
4.
Wu JeaJ. 2002. Org. Chem. 677908.
5.
Wu Jea. 2003. Chem. -Eur. J.. 9 2963.
6.
Hems WPea. 2007. Acc. Chem. Res.. 401340.
7.
Grasa GAeaJ. 2006. Organomet. Chem.. 6912332.
8.
Grasa GAea. 2005. Org. Lett.. 71449.
9.
Xu Lea. 2005. Chem. Commun..1390.
10.
Pye PJ, Rossen K, Reamer RA, Tsou NN, Volante RP, Reider PJ. 1997. A New Planar Chiral Bisphosphine Ligand for Asymmetric Catalysis:  Highly Enantioselective Hydrogenations under Mild Conditions. J. Am. Chem. Soc.. 119(26):6207-6208. https://doi.org/10.1021/ja970654g
11.
Pye PJ, Rossen K, Reamer RA, Volante R, Reider PJ. 1998. [2.2]PHANEPHOS-Ruthenium(II) complexes: Highly active asymmetric catalysts for the hydrogenation of ?-ketoesters. Tetrahedron Letters. 39(25):4441-4444. https://doi.org/10.1016/s0040-4039(98)00842-9
12.
Boaz NW, Debenham SD, Mackenzie EB, Large SE. 2002. Phosphinoferrocenylaminophosphines as Novel and Practical Ligands for Asymmetric Catalysis. Org. Lett.. 4(14):2421-2424. https://doi.org/10.1021/ol0261736
13.
Boaz NW, Large SE, Ponasik JA, Moore MK, Barnette T, Nottingham WD. 2005. The Preparation of Single Enantiomer 2-Naphthylalanine Derivatives Using Rhodium?MethylBoPhoz-catalyzed Asymmetric Hydrogenation. Org. Process Res. Dev.. 9(4):472-478. https://doi.org/10.1021/op050026g
Autenticati per continuare

Per continuare a leggere, autenticati o crea un account.

Non hai un Account?